{'fraction_non_alphanumeric': 0.030352748154224774, 'fraction_numerical': 0.008203445447087777, 'mean_word_length': 5.161616161616162, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hemodynamic characterization of bufuralol-HCl and pindolol based on the competitive effects of isoproterenol.

In this hemodynamic study a new beta-receptor blocker, Bufuralol-hydrochloride was compared with Pindolol under an Isoproterenol infusion with increasing doses in healthy male volunteers. We found the following results: 1. Before Isoproterenol peripheral resistance increased after acute i.v. application of Pindolol but decreased after Bufuralol-hydrochloride i.v. application. 2. After beta-receptor blockade with either Bufuralol-hydrochloride or with Pindolol a shift to the right of the dose effect relationship concerning heart rate and cardiac output under Isoproterenol infusion was observed, indicating beta 1-blockade. 3. The reduction of peripheral resistance which is usually observed as a sign of beta 2-blockade was also shifted to the right under the influence of both drugs. 4. This proves Bufuralol-hydrochloride to be a non-specific beta-blocking agent with an affinity to the beta 1- and beta 2-receptors. 5. Although Bufuralol-hydrochloride has a beta 2-blocking property which is even more pronounced than that of Pindolol, it reduces acutely, intravenously given, peripheral resistance.